“We are monitoring the cases closely and relooking at some of the unusual technical parameters in the wake of the reports raising concerns by the European regulator and the report by WHO,” a senior official, member of the national committee on adverse events following immunisation (AEFI) said.
In India, experts are looking at adverse events from both Covishield, as well as Bharat Biotech’s Covaxin. The result of the analysis is likely to be finalised by end of this week.
The official said the review is significant as globally regulators are waiting for India’s data because of the sheer number of doses of Covid vaccine administered here. “Besides, we also have a large scale AEFI monitoring and assessment mechanism already in place for the universal child immunisation programme,” he added.
On Wednesday, the European Medicines Agency (EMA) confirmed that the cases of blood clots with low blood platelets were associated with the administration of the AstraZeneca Covid-19 vaccine, but should still be listed as very rare side effects.
The World Health Organisation also said that a causal link between the AstraZeneca Covid-19 vaccine and the rare occurrence of blood clots with low platelets is “considered plausible but not confirmed”.
In an interim statement, the WHO’s Global Advisory Committee on Vaccine Safety (GACVS) said that the events under assessment are very rare, with low numbers reported among the almost 200 million individuals who have received the AstraZeneca vaccine around the world. However, specialised studies are needed to fully understand the potential link.
Meanwhile, several European countries have already halted or suspended the rollout of the vaccine in view of the reports.
Full report on www.toi.in